Grey Logo

Coco Therapeutics Ltd aims to develop a novel treatment for Alzheimer's disease directed towards the retinoic acid receptor-α.

159248_7679

CoCo Therapeutics Ltd Announces the Appointment of its Clinical and Scientific Advisory Group

CoCo Therapeutics Ltd, a newly formed UK Biotechnology Company today announced the appointment to its Clinical and Scientific Advisory Group of Clive Ballard, Jonathan Corcoran, Roy Lobb, Andrew Wood and Steve Butcher.

Read more...

CoCo Therapeutics Ltd Announces Appointment of Steve Butcher as Chief Operating Officer

CoCo Therapeutics Ltd, a newly formed biotechnology company, today announced the appointment of Dr Steve Butcher as Chief Operating Officer.

Read more...

New drug discovery company CoCo Therapeutics Ltd created to progress retinoic acid receptor alpha agonist for Alzheimer’s Disease

King’s College London, The Wellcome Trust and Advent Venture Partners today announced the formation of a new UK biotechnology company, CoCo Therapeutics Ltd, to progress the research of Professor Jonathan Corcoran into the development of new treatments for Alzheimer’s disease.

Read more...

Contact Us

Get in touch with your comments or enquiries:

Your Name (required)

Your Email (required)

Your Message

Enter Code:

captcha